CancerDrs

Head and Neck Cancer clinical trials in North Carolina

35 actively recruiting head and neck cancer trials at 32 sites across North Carolina.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 2, Phase 3 Recruiting NIH

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins i…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT01810913
Sites in North Carolina:
  • Atrium Health Stanly/LCI-Albemarle — Albemarle, North Carolina
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
  • Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
  • Atrium Health Pineville/LCI-Pineville — Charlotte, North Carolina
  • Atrium Health University City/LCI-University — Charlotte, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in North Carolina:
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
  • Margaret R Pardee Memorial Hospital — Hendersonville, North Carolina
  • FirstHealth of the Carolinas-Moore Regional Hospital — Pinehurst, North Carolina
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in North Carolina:
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.

Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in North Carolina:
  • Site 98 — Chapel Hill, North Carolina
  • Site 122 — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in North Carolina:
  • Carolina Cancer Research Center — Wilson, North Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

Sponsor: Merus B.V.
NCT ID: NCT06525220
Sites in North Carolina:
  • Site 113 — Durham, North Carolina
  • Site 118 — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in North Carolina:
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
  • Southeastern Medical Oncology Center-Clinton — Clinton, North Carolina
  • Southeastern Medical Oncology Center-Goldsboro — Goldsboro, North Carolina
  • Wayne Memorial Hospital — Goldsboro, North Carolina
  • Onslow Memorial Hospital — Jacksonville, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in North Carolina:
  • Southeastern Medical Oncology Center-Clinton — Clinton, North Carolina
  • Southeastern Medical Oncology Center-Goldsboro — Goldsboro, North Carolina
  • Southeastern Medical Oncology Center-Jacksonville — Jacksonville, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in North Carolina:
  • Randolph Hospital — Asheboro, North Carolina
  • UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
  • Cone Health Cancer Center — Greensboro, North Carolina
  • Annie Penn Memorial Hospital — Reidsville, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral muco…

Sponsor: NRG Oncology
NCT ID: NCT06532279
Sites in North Carolina:
  • Atrium Health Stanly/LCI-Albemarle — Albemarle, North Carolina
  • Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
  • Atrium Health Pineville/LCI-Pineville — Charlotte, North Carolina
  • Atrium Health University City/LCI-University — Charlotte, North Carolina
  • Atrium Health Cabarrus/LCI-Concord — Concord, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in North Carolina:
  • Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
  • Duke University Medical Center — Durham, North Carolina
  • East Carolina University — Greenville, North Carolina
  • Wake Forest University Health Sciences — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …

Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in North Carolina:
  • Duke University School of Medicine — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…

Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in North Carolina:
  • Carolina BioOncology Institute — Huntersville, North Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…

Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in North Carolina:
  • Carolina BioOncology Institute — Huntersville, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients. Over the course of the 10 week trial, mucositis, nephrotoxicity, and ot…

Sponsor: Matrix Biomed, Inc.
NCT ID: NCT03480971
Sites in North Carolina:
  • Wake Forest University Health Sciences — Winston-Salem, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

Esophageal cancer, which has a low 5-year overall survival rate (\<20%) is increasing in incidence. Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a significant number of esophageal cance…

Sponsor: VA Office of Research and Development
NCT ID: NCT05563766
Sites in North Carolina:
  • Durham VA Medical Center, Durham, NC — Durham, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…

Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in North Carolina:
  • University of North Carolina — Chapel Hill, North Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Sparing Parotid Ducts Via MRI Sialography for Reduced Patient-Reported Xerostomia

Radiation-induced xerostomia (dry mouth) is one of the most common and severe side effects for patients receiving radiation therapy for head and neck cancer. New approaches are needed to reduce this side effect and improve patients' qualit…

Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT07278557
Sites in North Carolina:
  • University of North Carolina at Chapel Hill, Department of Radiation Oncology — Chapel Hill, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Ce…

Sponsor: AbbVie
NCT ID: NCT05005403
Sites in North Carolina:
  • Duke Cancer Institute /ID# 276267 — Durham, North Carolina
  • Carolina BioOncology Institute /ID# 232597 — Huntersville, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting NIH

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach using chemotherapy together with radiation therapy ("chemo-radiation") in patients with head and neck cancer. Ipatasertib …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05172245
Sites in North Carolina:
  • Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
  • Atrium Health Cabarrus/LCI-Concord — Concord, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driv…

Sponsor: Bicara Therapeutics
NCT ID: NCT04429542
Sites in North Carolina:
  • Levine Cancer Institute — Charlotte, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

Sponsor: Dren Bio
NCT ID: NCT06999187
Sites in North Carolina:
  • Dren Investigational Site — Huntersville, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for part…

Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT ID: NCT07219212
Sites in North Carolina:
  • University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-711 as a monotherapy and in comb…

Sponsor: AbbVie
NCT ID: NCT07241039
Sites in North Carolina:
  • Carolina BioOncology Institute /ID# 272380 — Huntersville, North Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma

In this Phase I trial for subjects with advanced head \& neck cancer, breast cancer, soft tissue sarcoma or melanoma all subjects will receive open label X-PACT treatment as a intra-tumoral injection. The primary objective will be to estab…

Sponsor: Immunolight, LLC
NCT ID: NCT04389281
Sites in North Carolina:
  • Levine Cancer Institute — Charlotte, North Carolina
  • Duke University — Durham, North Carolina
View on ClinicalTrials.gov →

Showing 25 of 35 trials with sites in North Carolina. See all head and neck cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07